➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: July 24, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,900,638

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,900,638 protect, and when does it expire?

Patent 8,900,638 protects KAZANO and is included in one NDA.

This patent has thirty-one patent family members in twenty-five countries.

Summary for Patent: 8,900,638
Title:Solid preparation comprising alogliptin and metformin hydrochloride
Abstract: The present invention provides a solid preparation containing compound (I) [compound (I) is as defined in the specification] or a salt thereof, and metformin hydrochloride, which is useful as a therapeutic drug for diabetes and the like, and superior in the preservation stability. A solid preparation having a first part and a second part: a first part: a part containing compound (I) or a salt thereof and substantially free of metformin hydrochloride a second part: a part containing metformin hydrochloride and substantially free of compound (I) and a salt thereof.
Inventor(s): Yamamoto; Kazumichi (Osaka, JP), Koyama; Hiroyoshi (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:12/452,705
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,900,638
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Formulation; Use;

Drugs Protected by US Patent 8,900,638

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa KAZANO alogliptin benzoate; metformin hydrochloride TABLET;ORAL 203414-002 Jan 25, 2013 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Takeda Pharms Usa KAZANO alogliptin benzoate; metformin hydrochloride TABLET;ORAL 203414-001 Jan 25, 2013 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,900,638

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2007-188574Jul 19, 2007
PCT Information
PCT FiledJuly 16, 2008PCT Application Number:PCT/JP2008/063228
PCT Publication Date:January 22, 2009PCT Publication Number: WO2009/011451

International Family Members for US Patent 8,900,638

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 067557 ⤷  Free Forever Trial
Australia 2008276842 ⤷  Free Forever Trial
Brazil PI0814299 ⤷  Free Forever Trial
Canada 2694620 ⤷  Free Forever Trial
China 101801351 ⤷  Free Forever Trial
Colombia 6160301 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.